Using an unbiased open reading frame-based screening approach to identify genetic modifiers of EGFR in EGFR-mutant non-small cell lung cancer (NSCLC), Sharifnia et al. recently showed that overexpression of ITK overcomes the suppression of cell proliferation with erlotinib, an EGFR inhibitor [41]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.